Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle

被引:28
作者
Makoto, HA
Masashi, TA
Mitsuhiro, YB
Yamada, Y
机构
[1] Gifu Int Inst Biotechnol, Dept Gene Therapy, Gifu 5050116, Japan
[2] Inst Appl Biochem, Gifu 5050116, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Pathophysiol, Div Cardiovasc, Nagoya, Aichi, Japan
来源
PROSTAGLANDINS & OTHER LIPID MEDIATORS | 2002年 / 70卷 / 1-2期
关键词
platelet-activating factor acetylhydrolase; apolipoprotein E-deficient; atherosclerosis;
D O I
10.1016/S0090-6980(02)00015-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of increasing the activity of plasma platelet-activating factor (PAF) acetylhydrolase (AH) (PAF-AH) on the progression of atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice was examined by gene delivery to skeletal muscle. The expression vector pcDNA3.1 containing either human PAF-AH cDNA (pcDNA/PAF-AH) or green fluorescent protein cDNA (pcDNA/GFP) was introduced into the skeletal muscle of both hind legs of 6-week-old apoE(-/-) mice by electroporation. The activity of PAH-AH in plasma was significantly increased 4-16 weeks after electroporation of apoE(-/-) mice with 120 mug of pcDNA/PAF-AH; the maximal (2.5-fold) increase was apparent after 8 weeks. The mean thickness of the aortic wall, determined by 160 measurements in each mouse, was significantly reduced in apoE(-/-) mice 8-16 weeks after exposure to pcDNA/PAF-AH compared with that in corresponding control animals that received pcDNA/GFP. These results suggest that the electrotransfer of the plasma PAF-AH gene to skeletal muscle reduces the extent of atherosclerosis in apoE(-/-) mice. (C) 2002 Elsevier Science Inc. All lights reserved.
引用
收藏
页码:107 / 118
页数:12
相关论文
共 26 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   A mutation in plasma platelet-activating factor acetylhydrolase (Val(279)->Phe) is a genetic risk factor for stroke [J].
Hiramoto, M ;
Yoshida, H ;
Imaizumi, T ;
Yoshimizu, N ;
Satoh, K .
STROKE, 1997, 28 (12) :2417-2420
[3]   CLONING BY FUNCTIONAL EXPRESSION OF PLATELET-ACTIVATING-FACTOR RECEPTOR FROM GUINEA-PIG LUNG [J].
HONDA, Z ;
NAKAMURA, M ;
MIKI, I ;
MINAMI, M ;
WATANABE, T ;
SEYAMA, Y ;
OKADO, H ;
TOH, H ;
ITO, K ;
MIYAMOTO, T ;
SHIMIZU, T .
NATURE, 1991, 349 (6307) :342-346
[4]   PLATELET-ACTIVATING-FACTOR - A MEDIATOR FOR CLINICIAN [J].
IMAIZUMI, TA ;
STAFFORINI, DM ;
YAMADA, Y ;
MCINTYRE, TM ;
PRESCOTT, SM ;
ZIMMERMAN, GA .
JOURNAL OF INTERNAL MEDICINE, 1995, 238 (01) :5-20
[5]   Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II [J].
Matsuzawa, A ;
Hattori, K ;
Aoki, J ;
Arai, H ;
Inoue, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) :32315-32320
[6]   High-efficiency gene transfer into skeletal muscle mediated by electric pulses [J].
Mir, LM ;
Bureau, MF ;
Gehl, J ;
Rangara, R ;
Rouy, D ;
Caillaud, JM ;
Delaere, P ;
Branellec, D ;
Schwartz, B ;
Scherman, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4262-4267
[7]   MEASUREMENT OF PLATELET-ACTIVATING-FACTOR IN A CANINE MODEL OF CORONARY-THROMBOSIS AND IN ENDARTERECTOMY SAMPLES FROM PATIENTS WITH ADVANCED CORONARY-ARTERY DISEASE [J].
MUELLER, HW ;
HAUGHT, CA ;
MCNATT, JM ;
CUI, KX ;
GASKELL, SJ ;
JOHNSTON, DA ;
WILLERSON, JT .
CIRCULATION RESEARCH, 1995, 77 (01) :54-63
[8]  
Muramatsu T, 2001, INT J MOL MED, V7, P37
[9]   Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. [J].
Packard, CJ ;
O'Reilly, DSJ ;
Caslake, MJ ;
McMahon, AD ;
Ford, I ;
Cooney, J ;
Macphee, CH ;
Suckling, KE ;
Krishna, M ;
Wilkinson, FE ;
Rumley, A ;
Lowe, GDO .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1148-1155
[10]  
PATEL KD, 1992, J BIOL CHEM, V267, P15168